Ardelyx ^{Priced, Nasdaq: ARDX}

Developing therapies to control the progression of late-stage kidney disease.

Industry: Health Care

First Day Return: +0.8%

ARDX

Developing therapies to control the progression of late-stage kidney disease.

IPO News for Ardelyx

Kidney failure biotech Proteon Therapeutics sets terms for $61 million IPO 10/07/14
Ardelyx prices upsized IPO at $14 midpoint 06/19/14
12 US IPOs planned for the week of Jun 16 06/16/14

IPO Data
IPO Date	06/18/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$60
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Fremont, CA, United States
Founded	2007
Employees at IPO	37
Website www.ardelyx.com

IPO News for Ardelyx

Kidney failure biotech Proteon Therapeutics sets terms for $61 million IPO 10/07/14
Ardelyx prices upsized IPO at $14 midpoint 06/19/14
12 US IPOs planned for the week of Jun 16 06/16/14

Ardelyx (ARDX) Performance